TKToshihisa Kojima

Toshihisa Kojima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshihisa Kojima has a total of 226 co-authors. Here are the top co-authors by number of shared publications:

  • Naoki Ishiguro

    Aichi Developmental Disability Center, Aichi, Japan

    27 shared publications
  • Koji Funahashi

    Department of Orthopedic Surgery, Kariya Toyota General Hospital, Kariya, Japan

    20 shared publications
  • Masayo Kojima

    Department of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    15 shared publications
  • Shuji Asai

    Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan

    15 shared publications
  • Hisato Ishikawa

    Department of Orthopedic Surgery, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan

    14 shared publications
  • Nobunori Takahashi

    Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine , Nagoya, Japan

    13 shared publications

Latest Publications

  • Clinical Characteristics of Sarcopenia Among SARC ‐F‐Negative Patients With Rheumatoid Arthritis

    by Mochihito Suzuki, Shuji Asai, Toshihisa Kojima, Hiroto Yamamoto, Yuki Saito, Yuma Saito, Kenya Terabe, Yoshifumi Ohashi, Kaoru Nagai, Chinami Ohnishi, et al.

    Background: Sarcopenia is clinically important in patients with rheumatoid arthritis (RA) because chronic inflammation and physical dysfunction may contribute to muscle impairment. Although SARC‐F is widely used as a screening tool for sarcopenia, its diagnostic performance in patients with RA remains unclear. This study investigated the agreement between SARC‐F and Asian Working Group for Sarcopenia 2025 (AWGS2025)‐defined sarcopenia and evaluated clinical characteristics of sarcopenia in SARC‐F‐negative patients with RA. Methods: This cross‐sectional study included 212 patients with RA enrolled in a prospective cohort. Sarcopenia was diagnosed according to the AWGS2025 criteria. Agreement between SARC‐F and AWGS2025‐defined sarcopenia was assessed using sensitivity, specificity, overall agreement, and Cohen's kappa coefficient. Multivariable logistic regression and receiver operating characteristic (ROC) curve analyses were performed for SARC‐F‐negative patients. Results: The prevalence of SARC‐F positivity was 10.8%, whereas AWGS2025‐defined sarcopenia was observed in 25.0% of patients. Overall agreement between SARC‐F and AWGS2025‐defined sarcopenia was 72.6%, and Cohen's kappa coefficient was 0.10. Among SARC‐F‐negative patients, 23.3% had sarcopenia. Multivariable logistic regression analysis demonstrated that age and Health Assessment Questionnaire‐Disability Index (HAQ‐DI) were independently associated with sarcopenia. ROC analysis identified an optimal HAQ‐DI cutoff value of 0.25. Patients with sarcopenia showed lower walking speed and prolonged Timed Up and Go performance, despite negative SARC‐F results. Conclusions: Among SARC‐F‐negative patients with RA, a substantial proportion met the AWGS2025 diagnostic criteria for sarcopenia and showed impaired physical performance. These findings indicate that a negative SARC‐F case‐finding result does not necessarily preclude sarcopenia diagnosed according to the AWGS2025 criteria. Trial Registration: UMIN Clinical Trials Registry: UMIN000041034

  • Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey

    by Satoshi Takanashi, Yuko Kaneko, Yutaka Kawahito, Takashi Kida, Takahiko Sugihara, Toshihisa Kojima, Ryozo Harada, Michinori Ishitoku, Shintaro Hirata, Motomu Hashimoto, et al.

  • Risk factors for screw breakage in Lisfranc joint injuries: A multicenter retrospective study

    by Satoshi Muto, Yasuhiko Takegami, Toshihisa Kojima, Shiro Imagama

  • Top Cited Papers

    2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication

    by Masayoshi Harigai, Yuko Kaneko, Eiichi Tanaka, Shintaro Hirata, Hideto Kameda, Kayoko Kaneko, Mitsumasa Kishimoto, Masataka Kohno, Masayo Kojima, Toshihisa Kojima, et al.

    Objectives: The aim of this study is to update the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis (CPG for RA). Methods: The recommendations were developed based on the evidence published until the end of June 2022 using the Grading of Recommendations Assessment, Development, and Evaluation. The steering committee, CPG panel, systematic review (SR) group, and SR support team were organised. Results: The treatment goal and drug treatment algorithm required no modifications; however, the footnotes of the drug treatment algorithm were modified. SR of 21 new or updated recommendations for subcutaneous methotrexate (n = 1), biological disease-modifying antirheumatic drugs (n = 1), rituximab (n = 5), Janus kinase inhibitors (n = 6), biosimilars (n = 2), older patients (n = 4), and pregnancy and lactation (n = 2) was conducted. The recommendations for comorbidities and surgery and rehabilitation remained unchanged from the 2020 CPG for RA. Conclusions: The 2024 CPG for RA, which provide recommendations that reflect the current healthcare environment for rheumatoid arthritis in Japan, can be used effectively as a tool for shared decision-making between rheumatologists and patients in the treatment of RA.


  • Periprosthetic humeral fracture revision using a massive allograft in a patient with rheumatoid arthritis: A case report

    by Kenji Kishimoto, Toshihisa Kojima, Nobunori Takahashi, Shuji Asai, Kenya Terabe, Mochihito Suzuki, Yoshifumi Ohashi, Daisuke Kihira, Masataka Maeda, Masahiro Tatebe, et al.

    Total elbow arthroplasty (TEA) is a surgical option for patients with rheumatoid arthritis (RA). Periprosthetic fractures during and after TEA are one of the most common causes of reoperation. Fractures around the stem of a loose prosthesis with associated bone loss are the most technically challenging to treat. Previous reports have demonstrated that the use of massive allografts is a reasonable alternative in salvage situations. Here, we report the case of a 78-year-old woman with RA who underwent revision TEA using massive allografts with modifications to the methods described in previous reports. She suffered a right periprosthetic humeral fracture 5 years after primary TEA, with a fracture in the proximal humeral diaphysis and a long spiral fracture in the diaphysis. The fracture around the stem of a loose prosthesis was associated with bone loss. We performed revision TEA using an allograft of the proximal femoral diaphysis. In contrast to previous reports, we preserved part of the humeral diaphysis, which was thin due to osteolysis, without removal. The advantage of this approach was that it preserved attachments, such as the deltoid and brachioradialis muscles. The patient had good elbow function and minimal pain without adverse events at 1 year postoperatively. Our findings suggest that preserving part of a thinned humeral diaphysis is a reasonable option in revision TEA with a massive composite allograft.


  • Open Access

    Validation of grip strength as a measure of frailty in rheumatoid arthritis

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, Masayo Kojima, Shuji Asai, et al.

    Rheumatoid arthritis (RA) patients often exhibit finger/wrist joint symptoms and reduced grip strength. This study aimed to validate grip strength as a measure of frailty in RA patients. Subjects were 424 female RA patients (mean age ± standard deviation, 66.8 ± 14.5 years). Frailty was defined as a score of ≥ 8 points on the Kihon Checklist (KCL). Finger/wrist joint symptoms were defined based on tender or swollen joints. Associations between frailty and grip strength were determined using receiver operating characteristic (ROC) curve analysis and multivariable logistic regression analysis. There were 179 subjects with frailty (42.2%). Multivariable logistic regression analysis revealed that frailty was significantly associated with grip strength independently of finger/wrist joint symptoms. In ROC curves, cut-off scores of grip strength for frailty in subjects without and with finger/wrist joint symptoms were 17 kg (sensitivity, 62.1%; specificity, 69.0%) and 14 kg (sensitivity, 63.2%; specificity, 73.0%), respectively. The results of the present study suggest that grip strength in female RA patients is associated with frailty, with a cut-off score of 17 kg (equivalent to Cardiovascular Health Study criteria, < 18 kg) when RA patients have no finger/wrist joint symptoms. However, when RA patients have finger/wrist joint symptoms, it may be considered to reduce the cut-off score of grip strength.


  • Association between locomotive syndrome and methotrexate discontinuation due to adverse events in rheumatoid arthritis patients: A retrospective observational study

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, Masayo Kojima, Shuji Asai, et al.

  • Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study

    by Kenya Terabe, Nobunori Takahashi, Shuji Asai, Yuji Hirano, Yasuhide Kanayama, Yuichiro Yabe, Takeshi Oguchi, Takayoshi Fujibayashi, Hisato Ishikawa, Masahiro Hanabayashi, et al.

    Objectives: Patients with rheumatoid arthritis (RA) usually switch to a second biological disease-modifying antirheumatic drugs (bDMARDs) when the first has proven to be ineffective, although some may discontinue bDMARDs treatment altogether. We investigated the total rate of bDMARDs retention and the risk of bDMARDs discontinuation in patients with RA. Methods: The study included 564 patients with RA who started bDMARDs treatment before 2008 (<65 years old, n = 413; ≥65, n = 151). The primary outcome was the incidence of bDMARDs discontinuation due to adverse events (AEs). Risk factors were examined using Fine and Gray regression models. Results: Among 564 patients, 74 had discontinued bDMARDs treatment due to AEs. Male sex and Steinbrocker class 3–4 were more frequent, while rheumatoid factor and concomitant methotrexate treatment were less frequent, in those aged ≥65 years than in those aged <65 years, respectively. The subdistribution hazard ratio for discontinuation was significantly higher in the ≥65 group than in the <65 years group (hazard ratio = 3.53, 95% confidence interval = 2.07–6.03). Lack of concomitant treatment with MTX was risk factor for discontinuation in patients ≥65 years. Advanced Steinbrocker class was a risk factor in patients <65 years. Conclusions: Older patients are at higher risk of discontinuing bDMARDs treatment due to AEs than younger patients.


  • Open Access

    Validation of grip strength as a measure of frailty in rheumatoid arthritis

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Hiroshi Koshima, Nobuyuki Okui, Koji Funahashi, Hisato Ishikawa, Hidenori Inoue, Masayo Kojima, Shuji Asai, et al.

    Rheumatoid arthritis (RA) patients often exhibit finger/wrist joint symptoms and reduced grip strength. This study aimed to validate grip strength as a measure of frailty in RA patients. Subjects were 424 female RA patients (mean age±standard deviation, 66.8±14.5 years). Frailty was defined as a score of ≥8 points on the Kihon Checklist (KCL). Finger/wrist joint symptoms were defined based on tender or swollen joints. Associations between frailty and grip strength were determined using receiver operating characteristic (ROC) curve analysis and multivariable logistic regression analysis. There were 179 subjects with frailty (42.2%). Multivariable logistic regression analysis revealed that frailty was significantly associated with grip strength independently of finger/wrist joint symptoms. In ROC curves, cut-off scores of grip strength for frailty in subjects without and with finger/wrist joint symptoms were 17 kg (sensitivity, 62.1%; specificity, 69.0%) and 14 kg (sensitivity, 63.2%; specificity, 73.0%), respectively. The results of the present study suggest that grip strength in female RA patients is associated with frailty, with a cut-off score of 17 kg (equivalent to Cardiovascular Health Study criteria, <18 kg) when RA patients have no finger/wrist joint symptoms. However, when RA patients have finger/wrist joint symptoms, measures other than grip strength such as lower limb function should be considered.


  • Top Cited Papers
    Open Access

    Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis—secondary publication

    by Yutaka Kawahito, Akio Morinobu, Yuko Kaneko, Masataka Kohno, Shintaro Hirata, Mitsumasa Kishimoto, Yohei Seto, Takahiko Sugihara, Eiichi Tanaka, Hiromu Ito, et al.

    Objective: The aim of this study was to update the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for RA) according to recent changes in the medical environment in Japan. This article is a digest version of the guidance.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation method to update the 2014 JCR CPG for RA. A consensus was formed by CPG panel members.Results: We identified 36 important clinical questions regarding drug treatment and developed corresponding recommendations for RA. The recommendations included the following RA medications: non-steroidal anti-inflammatory drugs, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, anti-receptor activator for nuclear factor-κB ligand antibodies, and Janus kinase inhibitors, as well as the tapering and discontinuation of these medications. Recommendations regarding the efficacy and safety of treatments in the elderly and patients with comorbidities were also developed. Finally, we used these recommendations to create an original algorithm for drug treatment for RA based on the Treat-to-Target approach.Conclusion: The 2020 JCR CPG for RA provides a useful tool for rheumatologists, health care professionals, and patients with RA, enabling shared decision-making in a variety of clinical situations.